anti–PD-L1 antibodies

Anti-PD-L1 antibodies are a class of monoclonal antibodies that function as immune checkpoint inhibitors by targeting the Programmed Death-Ligand 1 (PD-L1) protein. PD-L1 is often overexpressed on the surface of tumor cells and tumor-infiltrating immune cells, where it binds to the PD-1 receptor on T cells to inhibit their cytotoxic activity, allowing the tumor to evade immune detection. By blocking this interaction, anti-PD-L1 antibodies restore the anti-tumor T-cell response. This therapeutic class includes several agents such as atezolizumab, durvalumab, and avelumab, which are utilized across various oncology indications. In clinical research, such as studies conducted by Zhongshan Hospital, Fudan University, these antibodies are being evaluated for their efficacy in patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) gastric and gastroesophageal junction adenocarcinomas, where high mutational burdens often correlate with improved response to checkpoint blockade.

Other names

anti-PD-L1 antibodiesanti-PD-L-1 antibodiesanti-PD-L 1 antibodiesPD-L1 inhibitorsPD-L-1 inhibitorsPD-L 1 inhibitorsprogrammed death-ligand 1 antibodiesanti-programmed death-ligand 1 antibodies